39 studies found for:    melanoma | Open Studies | interleukin-2
Show Display Options
Rank Status Study
21 Recruiting Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: High Dose Interleukin-2 (IL-2);   Procedure: ACT with TIL Infusion;   Drug: Vemurafenib;   Drug: Lymphodepletion
22 Recruiting Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients
Condition: Metastatic Melanoma
Intervention: Drug: Proleukin and Dacarbazine
23 Recruiting Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2
Condition: Metastatic Melanoma or Renal Cell Carcinoma
Intervention: Other: Boost of radiotherapy + high dose IL-2 treatment
24 Recruiting Study of Cell Transfer Therapy for Metastatic Melanoma Using 4-1BB Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy
Conditions: Melanoma;   Skin Cancer
Interventions: Drug: Interleukin-2;   Drug: Fludarabine;   Drug: Cylcophosphamide;   Genetic: 41BB Selected Tumor Infiltrating Lymphocytes
25 Recruiting Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells;   Drug: non-myeloablative conditioning chemotherapy
26 Recruiting Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III -IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: ziv-aflibercept;   Biological: aldesleukin;   Other: laboratory biomarker analysis
27 Unknown  The Role of Peptide-Loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2
Condition: Metastatic Melanoma
Intervention: Procedure: Immunotherapy treatment for melanoma
28 Recruiting Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Biological: therapeutic tumor infiltrating lymphocytes;   Biological: aldesleukin;   Other: laboratory biomarker analysis
29 Recruiting Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Condition: Metastatic Melanoma
Interventions: Drug: Ipilimumab;   Procedure: Tumor Infiltrating Lymphocytes (TIL);   Drug: Administration of Lymphodepletion;   Drug: Cyclophosphamide as Part of Lymphodepletion;   Drug: Fludarabine as Part of Lymphodepletion;   Drug: High Dose IL-2;   Biological: Adoptive Cell Therapy with TIL
30 Recruiting HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: vemurafenib + HD IL-2
31 Recruiting Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2
Condition: Metastatic Malignant Melanoma and Renal Cell Carcinoma
Intervention: Biological: Irradiated donor lymphocyte infusion
32 Recruiting IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma
Condition: Malignant Melanoma
Intervention: Other: Observation
33 Unknown  Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-Depleting Chemotherapy
Condition: Metastatic Melanoma
Intervention: Biological: tumor infiltrating lymphocytes
34 Recruiting Study of Ipilimumab Administered to Stage IIIC and Stage IV Melanoma Patients After Regulatory T Cell Depletion With Denileukin Diftitox
Conditions: Stage IIIC Melanoma;   Stage IV Melanoma
Intervention: Drug: Ipilimumab
35 Recruiting A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
Condition: Metastatic Melanoma Stage IV
Interventions: Drug: Arm 1: L19IL2 + Dacarbazine;   Drug: Arm 2: Dacarbazine
36 Recruiting Intratumoral Administration of L19IL2/L19TNF
Condition: Malignant Melanoma, Skin
Intervention: Drug: L19IL2+L19TNF
37 Recruiting Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
Conditions: Solid Tumour,;   Breast Cancer,;   Metastatic Melanoma,;   Non-small Cell Lung Cancer (NSCLC),
Intervention: Drug: F16IL2 in combination with paclitaxel
38 Recruiting Phase I/II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin
Condition: Metastatic Cancer That Express the MAGE-A3-DP4 Antigen
Interventions: Genetic: Anti-MAGE-A3-DP4 TCR PBL;   Drug: Interleukin-2;   Drug: Fludarabine;   Drug: Cyclophosphamide
39 Unknown  Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment
Condition: Depression
Interventions: Drug: Escitalopram;   Drug: Placebo;   Drug: IL-2

Show previous page of results Previous Page (1-20) Studies Shown (21-39) Next Page
Indicates status has not been verified in more than two years